Erectile Dysfunction - Pipeline Review, H2 2019

Published by Global Markets Direct on 11th November 2019 | Ref: 1463973 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Erectile Dysfunction - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H2 2019, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 3, 3, 7, 14, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).

- The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Erectile Dysfunction - Overview

Erectile Dysfunction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Erectile Dysfunction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Erectile Dysfunction - Companies Involved in Therapeutics Development

Aquestive Therapeutics Inc

Astellas Pharma Inc

Biozeus Pharmaceutical SA

Can-Fite BioPharma Ltd

CardioVascular BioTherapeutics Inc

Cure Pharmaceutical Inc

Fabre-Kramer Pharmaceuticals Inc

Futura Medical Plc

Hemostemix Inc

Humanetics Corp

Karessa Pharma Holding AB

Mezzion Pharma Co Ltd

Mitsubishi Tanabe Pharma Corp

NAL Pharmaceuticals Ltd

Pharmicell Co Ltd

Saniona AB

SK Chemicals Co Ltd

Suda Pharmaceuticals Ltd

Targazyme Inc

XuanZhu Pharma Co Ltd

Yangtze River Pharmaceutical Group

Erectile Dysfunction - Drug Profiles

(finasteride + tadalafil) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACP-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGM-175 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alprostadil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AN-788 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-185 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avanafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BZ-371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellgram-ED - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVBT-141 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FKK-01PD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genistein - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ILG-F - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPED-2015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

libiguins - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MED-2002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirabegron ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RNAi Gene therapy to Inhibit FL2 for Erectile Dysfunction, Burns and Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SID-123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PDE5 for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUD-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil IR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TF-0092 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPN-729 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udenafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vardenafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vardenafil hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-5849 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Yonkenafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Erectile Dysfunction - Dormant Projects

Erectile Dysfunction - Discontinued Products

Erectile Dysfunction - Product Development Milestones

Featured News & Press Releases

Oct 28, 2019: New clinical data provide additional validation for the safety and efficacy of Futura Medical’s topical MED2005 in the treatment of erectile dysfunction

Oct 21, 2019: Final dosing of last patient in MED2005 phase 3 study

Oct 15, 2019: Futura Medical to present data on MED2005 for the treatment of erectile dysfunction at the 20th Annual Fall Scientific Meeting of SMSNA and Host Advisory Meeting

Sep 27, 2019: Initiator Pharma starts dosing of last the patients in the IPED2015 clinical trial

Sep 03, 2019: Initiator Pharma receives commitment of support for IPED2015 from Innovation Fund Denmark

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1463973 | GMDHC11408IDB

Number of Pages

137

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
23-01-2018

$2,000 USD

Published by Global Markets Direct
18-07-2017

$2,000 USD

Published by Global Markets Direct
28-02-2017

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Erectile Dysfunction - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.